Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
nesvacumab · 2 trials · 1 indication
Determine the maximum tolerable dose or recommended phase 2 dose of nesvacumab (REGN910/ SAR307746) administered in combination with aflibercept (ziv-aflibercept) in patients with advanced solid malignancies
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | - |
| Cohort 2 | EXPERIMENTAL | - |
| Cohort 3a | EXPERIMENTAL | - |
| Cohort 3b | EXPERIMENTAL | - |
| Cohort 4 | EXPERIMENTAL | - |
| Cohort 3 | EXPERIMENTAL | Dose 3 |
| Cohort 5 | EXPERIMENTAL | Dose 5 |
| Expansion Cohort 1 | EXPERIMENTAL | Dose 4 |
| Expansion Cohort 2 | EXPERIMENTAL | Dose 5 |
| Name | Type | Description |
|---|---|---|
| nesvacumab (REGN910/ SAR307746) | DRUG | Dose level 1 |
| aflibercept (ziv-aflibercept) | DRUG | Dose level 1 |
Inclusion Criteria: Inclusion criteria include, but are not limited to, the following: 1. Confirmed diagnosis of solid tumor malignancy 2. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 3. Adequate hepatic, renal and bone marrow function 4. Resolution of toxicity from prior th...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
Nesvacumab is an investigational drug being studied for the treatment of solid tumors. It is a small molecule developed by Regeneron Pharmaceuticals, Inc. (REGN). As of the available data, nesvacumab is in Phase 1 clinical development and has not been approved by the FDA.
Nesvacumab is being developed by Regeneron Pharmaceuticals, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol REGN. The drug is in Phase 1 clinical development for the treatment of solid tumors.
Nesvacumab is in Phase 1 clinical development. It is an investigational drug for solid tumors and has not been approved by regulatory authorities. Two Phase 1 trials have been completed, with a total of 101 participants enrolled.
Nesvacumab has been studied in two completed Phase 1 clinical trials. The first, NCT01271972, enrolled 53 participants with solid tumors. The second, NCT01688960, enrolled 48 participants with advanced solid malignancies and evaluated nesvacumab in combination with aflibercept. Both trials were conducted in the United States and Canada.
Yes, nesvacumab is also known as REGN910 and SAR307746. These alternative names appear in the titles of its clinical trials, such as NCT01271972 and NCT01688960, which refer to the drug by these identifiers.